Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ADAPT-C: Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC

NCT04585490 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT04585490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04585490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ADAPT-C: Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
Lead sponsor
Stanford University
Phase
Phase 3
Overall status
Recruiting
Start date
August 25, 2021
Completion date
April 30, 2028
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, nsclc, nsclc, stage iii